Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azenta, Inc.AZTA · Entity 4724 | Interim CEO | September 22, 2026 | September 23, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2026 | July 28, 2026 |
| Quanterix CorpQTRX · Entity 6649 | Director | January 02, 2025 | January 06, 2025 |
| REPLIGEN CORPRGEN · Entity 486 | Director | May 14, 2026 | May 18, 2026 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director | October 20, 2023 | October 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azenta, Inc.
Report date September 22, 2026 · Filed September 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 42,602 |
Reported balance
After 2026-09-22 transaction · row 1
1 source rowRow 1 · 2026-09-22 · Tax withholding · Disposed 1,456 · Balance 42,602 F1: Shares withheld by the Company to satisfy tax withholding obligations arising from the vesting and settlement on September 22, 2026, of 3,055 restricted stock units held by the Reporting Person. This transaction does not represent a sale of securities by the Reporting Person in the market. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Company to satisfy tax withholding obligations arising from the vesting and settlement on September 22, 2026, of 3,055 restricted stock units held by the Reporting Person. This transaction does not represent a sale of securities by the Reporting Person in the market.
HAEMONETICS CORP
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,538 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,538 · Balance 2,538 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Quanterix Corp
Report date January 02, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,908 |
Reported balance
After 2025-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 7,435 · Balance 36,908 F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2025 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2: Includes 7,435 restricted stock units. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.76 · Expires 2035-01-02 | Direct | 15,821 |
Reported balance
After 2025-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-01-02 · Grant · Acquired 15,821 · Balance 15,821 F3: Represents non-qualified stock option to purchase 15,821 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. |
| Common StockSEC Table I · non-derivative | IndirectHeld by trust | 254,633 |
Reported balance
Holding disclosure · report date 2025-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 254,633 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest as to 100% of the shares on December 31, 2025 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
F2: Includes 7,435 restricted stock units.
F3: Represents non-qualified stock option to purchase 15,821 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy.
REPLIGEN CORP
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,581 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 995 · Balance 6,581 F1: Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14 | Direct | 2,239 |
Reported balance
After 2026-05-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |
| Common StockSEC Table I · non-derivative | IndirectBy Martin D. Madaus 2011 Revocable Trust | 1,800 |
Reported balance
Holding disclosure · report date 2026-05-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,800 |
| Common StockSEC Table I · non-derivative | IndirectSpouse Trust | 11 |
Reported balance
Holding disclosure · report date 2026-05-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 11 |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Madaus was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
STANDARD BIOTOOLS INC.
Report date October 20, 2023 · Filed October 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,111 |
Reported balance
After 2023-10-20 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-10-20 · Grant · Acquired 1,574 · Balance 104,111 F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest 100% on December 15, 2023. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control. F2: The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $4,000 in cash compensation for services as a committee memeber. The share price is based on the Fair Market Value as of the first date of quarterly trading window following the date on which the Reporting Person's new committe assignment was approved by the Board. F3: Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest 100% on December 15, 2023. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control.
F2: The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $4,000 in cash compensation for services as a committee memeber. The share price is based on the Fair Market Value as of the first date of quarterly trading window following the date on which the Reporting Person's new committe assignment was approved by the Board.
F3: Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HOLOGIC INC
Report date April 07, 2026 · Filed April 09, 2026
Section 16 reporting ended · disclosed 2026-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Disposition to issuer · Disposed 5,396 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 0 |
Reported balance
After 2026-04-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-04-07 · Disposition to issuer · Disposed 5,445 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration"). F3: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.79 · Expires 2034-12-09 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Disposition to issuer · Disposed 1,016 · Balance 0 F4: For Footnote (4), see Remarks below. |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.36 · Expires 2035-02-26 | Direct | 0 |
Reported balance
After 2026-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-07 · Disposition to issuer · Disposed 5,535 · Balance 0 F4: For Footnote (4), see Remarks below. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 21, 2025 (the "Merger Agreement"), by and among Hologic, Inc. ("Hologic" or "Company"), Hopper Parent Inc., a Delaware corporation ("Parent"), and Hopper Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of Hologic common stock, par value $0.01 ("Company Common Stock"), was converted into the right to receive (x) $76.00 per share in cash, without interest (the "Cash Consideration") and (y) one (1) contingent value right, which represents the right to receive up to $3.00 in cash, when and if payable (each, a "CVR") (the consideration contemplated by clauses (x) and (y), together, the "Merger Consideration").
F2: At the Effective Time, each time-vesting restricted stock unit award (a "Company RSU Award") held directly by the reporting person was converted into the right to receive the Merger Consideration in respect of each share of Company Common Stock underlying the Company RSU Award. As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F3: As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Company Common Stock.
F4: For Footnote (4), see Remarks below.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 5, 2022 21:06 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 427 | $42.41 | $18,109.07 |
DisclosureSEC source: 0001562180-22-000231 · primarydocument.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,443 F3 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the fourth quarter of 2021. F4 · price: Closing price of the Company's common stock on the Nasdaq Global Market on January 3, 2022. F2 · balance_after: Includes 2,668 restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:06 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000231 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,016 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2022 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,668 restricted stock units. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:01 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 354 | $51.18 | $18,117.72 |
DisclosureSEC source: 0001562180-21-006297 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,348 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2021. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2021. F3 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:16 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 304 | $59.48 | $18,081.92 |
DisclosureSEC source: 0001562180-21-004771 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,994 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2021. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 1, 2021. F3 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| April 01, 2021 Filed Apr 3, 2021 01:44 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 294 | $61.45 | $18,066.30 |
DisclosureSEC source: 0001562180-21-002585 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,690 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the first quarter of 2021. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on April 1, 2021. F3 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:54 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $44.10 | $0.00 |
DisclosureSEC source: 0001562180-21-000099 · primarydocument.xml · derivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2031-01-04 F6 · shares: Represents non-qualified stock option to purchase 7,900 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:54 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 410 | $44.11 | $18,085.10 |
DisclosureSEC source: 0001562180-21-000099 · primarydocument.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,396 F3 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the fourth quarter of 2020. F4 · price: Closing price of the Company's common stock on the Nasdaq Global Market on January 4, 2021. F2 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 22:54 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000099 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,986 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2021 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,270 restricted stock units. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:01 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,372 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001562180-20-006579 · primarydocument.xml · derivative · entry 7 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,372 shares Expires 2021-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:01 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,372 | $42.45 | $58,241.40 |
DisclosureSEC source: 0001562180-20-006579 · primarydocument.xml · nonDerivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,716 F2 · shares: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 21:01 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,372 | $2.28 | $3,128.16 |
DisclosureSEC source: 0001562180-20-006579 · primarydocument.xml · nonDerivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:01 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001562180-20-006579 · primarydocument.xml · derivative · entry 6 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,372 Underlying: Common Stock · 1,600 shares Expires 2021-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:01 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $39.40 | $63,040.00 |
DisclosureSEC source: 0001562180-20-006579 · primarydocument.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,716 F2 · shares: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:01 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $2.28 | $3,648.00 |
DisclosureSEC source: 0001562180-20-006579 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:24 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001562180-20-006395 · primarydocument.xml · derivative · entry 7 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,972 Underlying: Common Stock · 1,600 shares Expires 2021-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:24 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $42.57 | $68,112.00 |
DisclosureSEC source: 0001562180-20-006395 · primarydocument.xml · nonDerivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,716 F2 · shares: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:24 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $2.28 | $3,648.00 |
DisclosureSEC source: 0001562180-20-006395 · primarydocument.xml · nonDerivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:24 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001562180-20-006395 · primarydocument.xml · derivative · entry 6 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,572 Underlying: Common Stock · 1,600 shares Expires 2021-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:24 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $44.59 | $71,344.00 |
DisclosureSEC source: 0001562180-20-006395 · primarydocument.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,716 F2 · shares: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| October 19, 2020 Filed Oct 20, 2020 20:24 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $2.28 | $3,648.00 |
DisclosureSEC source: 0001562180-20-006395 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:43 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001562180-20-006329 · primarydocument.xml · derivative · entry 7 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,172 Underlying: Common Stock · 1,600 shares Expires 2021-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:43 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $37.17 | $59,472.00 |
DisclosureSEC source: 0001562180-20-006329 · primarydocument.xml · nonDerivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,716 F2 · shares: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:43 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $2.28 | $3,648.00 |
DisclosureSEC source: 0001562180-20-006329 · primarydocument.xml · nonDerivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 21:43 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001562180-20-006329 · primarydocument.xml · derivative · entry 6 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,772 Underlying: Common Stock · 1,600 shares Expires 2021-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 21:43 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $36.47 | $58,356.96 |
DisclosureSEC source: 0001562180-20-006329 · primarydocument.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,716 F2 · shares: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F3 · price: This transaction was executed in multiple trades at prices ranging from $36.4596 to $36.675. The price reported reflects the weighted average sale price. The reporting person undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 21:43 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $2.28 | $3,648.00 |
DisclosureSEC source: 0001562180-20-006329 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:23 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 520 | $34.70 | $18,044.00 |
DisclosureSEC source: 0001562180-20-006293 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,716 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2020, pursuant to an election made in December 2019. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2020. F3 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 20:10 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 142 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001562180-20-006152 · primarydocument.xml · derivative · entry 10 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,372 Underlying: Common Stock · 142 shares Expires 2021-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 20:10 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,458 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-20-006152 · primarydocument.xml · derivative · entry 9 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,458 shares Expires 2021-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 20:10 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 142 | $32.80 | $4,657.60 |
DisclosureSEC source: 0001562180-20-006152 · primarydocument.xml · nonDerivative · entry 6 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,196 F2 · shares: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 20:10 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 142 | $2.28 | $323.76 |
DisclosureSEC source: 0001562180-20-006152 · primarydocument.xml · nonDerivative · entry 5 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 20:10 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,458 | $32.49 | $47,367.07 |
DisclosureSEC source: 0001562180-20-006152 · primarydocument.xml · nonDerivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,196 F2 · shares: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 20:10 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,458 | $1.93 | $2,813.94 |
DisclosureSEC source: 0001562180-20-006152 · primarydocument.xml · nonDerivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:10 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-20-006152 · primarydocument.xml · derivative · entry 8 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458 Underlying: Common Stock · 1,600 shares Expires 2021-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:10 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $33.09 | $52,944.00 |
DisclosureSEC source: 0001562180-20-006152 · primarydocument.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,196 F2 · shares: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 20:10 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $1.93 | $3,088.00 |
DisclosureSEC source: 0001562180-20-006152 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 21:49 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (right to buy) · Derivative | 1,600 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-20-006035 · primarydocument.xml · derivative · entry 8 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,057 Underlying: Common Stock · 1,600 shares Expires 2021-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 21:49 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $32.43 | $51,888.00 |
DisclosureSEC source: 0001562180-20-006035 · primarydocument.xml · nonDerivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,196 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 21:49 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $1.93 | $3,088.00 |
DisclosureSEC source: 0001562180-20-006035 · primarydocument.xml · nonDerivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 21:49 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (right to buy) · Derivative | 693 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-20-006035 · primarydocument.xml · derivative · entry 7 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,657 Underlying: Common Stock · 693 shares Expires 2021-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 21:49 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 907 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-20-006035 · primarydocument.xml · derivative · entry 6 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 907 shares Expires 2021-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 21:49 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $33.16 | $53,056.00 |
DisclosureSEC source: 0001562180-20-006035 · primarydocument.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,196 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 21:49 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $1.93 | $3,088.00 |
DisclosureSEC source: 0001562180-20-006035 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 23:44 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-20-005876 · primarydocument.xml · derivative · entry 7 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907 Underlying: Common Stock · 1,600 shares Expires 2021-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 23:44 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $35.08 | $56,128.00 |
DisclosureSEC source: 0001562180-20-005876 · primarydocument.xml · nonDerivative · entry 4 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,196 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 23:44 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $1.93 | $3,088.00 |
DisclosureSEC source: 0001562180-20-005876 · primarydocument.xml · nonDerivative · entry 3 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:44 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-20-005876 · primarydocument.xml · derivative · entry 6 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,507 Underlying: Common Stock · 1,600 shares Expires 2021-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:44 UTC | Quanterix Corp QTRX · Entity 6649 | SaleCommon Stock | 1,600 | $35.37 | $56,592.00 |
DisclosureSEC source: 0001562180-20-005876 · primarydocument.xml · nonDerivative · entry 2 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,196 F2 · kind: All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 9, 2019. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| September 01, 2020 Filed Sep 3, 2020 23:44 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 1,600 | $1.93 | $3,088.00 |
DisclosureSEC source: 0001562180-20-005876 · primarydocument.xml · nonDerivative · entry 1 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,270 Restricted Stock Units. Read SEC document |
| August 19, 2020 Filed Aug 20, 2020 20:32 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-20-005580 · primarydocument.xml · derivative · entry 7 Madaus Martin D · CIK 0001310268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,107 Underlying: Common Stock · 1,600 shares Expires 2021-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All options are vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.